XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Statement of profit or loss and other comprehensive income - AUD ($)
 6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue and other income    
Other income $ 0 $ 24,956
Finance Income 139 1,989
Expenses    
Research and development expense (9,359,972) (10,988,075)
General and administrative expense (4,276,514) (2,482,582)
Loss on revaluation of contingent consideration (85,226) (74,110)
Loss before income tax benefit (13,721,573) (13,517,822)
Income tax benefit 135,546 315,974
Loss after income tax benefit for the half-year attributable to the owners of Kazia Therapeutics Limited (13,586,027) (13,201,848)
Items that may be reclassified subsequently to profit or loss    
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax 86,494 6,946
Other comprehensive income for the half-year, net of tax 86,494 6,946
Total comprehensive income for the half-year attributable to the owners of Kazia Therapeutics Limited $ (13,499,533) $ (13,194,902)
Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited    
Basic earnings per share $ (9.327) $ (10)
Diluted earnings per share $ (9.327) $ (10)